Headache Disorders
Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatmen...
-д хадгалсан:
| Формат: | Online |
|---|---|
| Хэл сонгох: | англи |
| Хэвлэсэн: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| Нөхцлүүд: | |
| Онлайн хандалт: | ONIX_20250812T110751_9783725843473_444 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|